Dechra acquires worldwide rights to verdinexor
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO.596/2014.
Tuesday, 11 January 2022
Dechra® Pharmaceuticals PLC
(Dechra, Group, Company)
Acquisition
Dechra acquires the worldwide rights to verdinexor for dogs
The Board of Dechra is pleased to announce that it has agreed terms with Anivive Lifesciences, Inc to acquire the worldwide rights to verdinexor, a novel treatment of all forms and stages of canine lymphoma in dogs. Under the terms of the agreement Dechra will acquire the global product rights and a first right of refusal for other species along with the trademark (Laverdia®).
The product, currently sold as LAVERDIA-CA1 in the USA is a novel oral SINE (selective inhibitor of nuclear export) drug and the first oral tablet for canine lymphoma. It was conditionally approved by the FDA Center for Veterinary Medicine on 11 January 2021. Dechra will acquire the worldwide marketing rights, the rights to the intellectual property, the marketing authorisations (when granted) and associated regulatory documentation, supply contracts with third parties in relation to the raw material and manufacture of the finished product. No other assets are being transferred to Dechra.
Sales of the product in the USA commenced under the conditional approval in July 2021. Full dossier submissions are planned for USA, UK, EU, Brazil, Australia, Japan and Canada.
Ian Page, Dechra's Chief Executive Officer commented:
"We are delighted to acquire the worldwide rights to Laverdia. Its addition to our portfolio will expand Dechra into a new, niche therapy area, while also offering veterinarians and dog owners a simple to use, effective medication for lymphoma that extends the time a family has with their pet."
|
Enquiries: |
|
|
Dechra Pharmaceuticals PLC |
Office: +44 (0) 1606 814 730 |
|
Ian Page, Chief Executive Officer |
|
|
Paul Sandland, Chief Financial Officer e-mail: corporate.enquiries@dechra.com |
|
|
|
|
|
TooleyStreet Communications Ltd |
Mobile: +44 (0) 7785 703 523 |
|
Fiona Tooley, Director e-mail: fiona@tooleystreet.com |
|
About Dechra
Dechra is global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com .
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
About Laverdia
LAVERDIA-CA1 is a new oral treatment option for canine lymphoma. It is the first small-molecule selective inhibitor of nuclear export (SINE) drug specifically designed for veterinarian use. It employs a novel targeted mechanism of action where it targets and binds to Exportin 1 (XPO1)-a "transport" protein that proliferates in certain types of cancer. Excessive amounts of XPO1 export important tumour suppressing proteins (TSPs)-necessary for fighting cancer-from the nuclei of cells, rendering them vulnerable to uncontrolled growth. With its targeted blocking of XPO1, LAVERDIA-CA1 allows for TSPs to be trapped inside the cell nucleus, triggering programmed cell death of lymphoma cells while sparing healthy cells.
About Anivive Lifesciences, Inc
Anivive Lifesciences, Inc, a US-based company, is a next-generation pet health drug discovery and commercialization company that dramatically improves the speed and cost of addressing unmet medical needs in pets. Using a novel technology and analytics platform, Anivive discovers first-in-class therapeutics for unmet conditions in pets.
For more information, please visit: www.anivive.com .
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain inside information stipulated under the Market Abuse (Amendment) (EU Exit) Regulations 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 7 hours ago Luceco
- 8 hours ago Helios Towers
- 8 hours ago Wise Class A
- 8 hours ago EDX Medical Group Plc
- 8 hours ago Naked Wines